Viatris (VTRS) Income from Continuing Operations (2019 - 2026)
Viatris (VTRS) posted quarterly Income from Continuing Operations of 176400000.0 for Q1 2026, up 105.8% year-over-year from 85714778.61 in Q1 2025, and up 151.87% quarter-over-quarter from 340100000.0 in Q4 2025.
Viatris (VTRS) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Viatris' Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 176400000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 105.8% year-over-year to 176400000.0; the TTM figure through Mar 2026 stood at 296500000.0 (up 92.18% YoY), while the FY2025 annual figure was 3514900000.0, down 454.23% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 176400000.0, up from 340100000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 1011200000.0 in Q4 2022, with the low at 3042000000.0 in Q1 2025.
- The 5-year median for Income from Continuing Operations is 113900000.0 (2024), against an average of 108200000.0.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations soared 483.32% in 2022, then sank 2770.76% in 2025.
- Viatris' Income from Continuing Operations stood at 1011200000.0 in 2022, then tumbled by 175.71% to 765600000.0 in 2023, then soared by 32.54% to 516500000.0 in 2024, then soared by 34.15% to 340100000.0 in 2025, then soared by 151.87% to 176400000.0 in 2026.
- Business Quant data shows VTRS's Income from Continuing Operations at 176400000.0 in Q1 2026, 340100000.0 in Q4 2025, and 128200000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.31 Bn | 39.66 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.65 Bn | 29.98 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.18 Bn | 19.52 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.82 Bn | 17.94 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.70 Bn | 15.31 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Alkermes | 8.21 Bn | 7.55 Bn | 397.90 Mn | 524,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -118.80 Mn |
| Mar 31, 2026 | 176.40 Mn |
| Dec 31, 2025 | -340.10 Mn |
| Sep 30, 2025 | -128.20 Mn |
| Jun 30, 2025 | -4.60 Mn |
| Mar 31, 2025 | -3.04 Bn |
| Dec 31, 2024 | -516.50 Mn |
| Sep 30, 2024 | 94.80 Mn |
| Jun 30, 2024 | -326.40 Mn |
| Mar 31, 2024 | 113.90 Mn |
| Dec 31, 2023 | -765.60 Mn |
| Sep 30, 2023 | 331.60 Mn |
| Jun 30, 2023 | 264.00 Mn |
| Mar 31, 2023 | 224.70 Mn |
| Dec 31, 2022 | 1.01 Bn |
| Sep 30, 2022 | 354.30 Mn |
| Jun 30, 2022 | 313.90 Mn |
| Mar 31, 2022 | 399.20 Mn |
| Dec 31, 2021 | -263.80 Mn |
| Sep 30, 2021 | 311.50 Mn |